Motoko Maekawa
Affiliations: | Laboratory for Molecular Psychiatry | RIKEN Center for Brain Science |
Google:
"Motoko Maekawa"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Maekawa M. (2023) [The nuclear receptor PPARα (peroxisome proliferator-activated receptor α) as a novel therapeutic target for schizophrenia]. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica |
| Balan S, Iwayama Y, Ohnishi T, et al. (2021) A loss-of-function variant in SUV39H2 identified in autism-spectrum disorder causes altered H3K9 trimethylation and dysregulation of protocadherin β-cluster genes in the developing brain. Molecular Psychiatry |
| Ohnishi T, Kiyama Y, Arima-Yoshida F, et al. (2021) Cooperation of LIM domain-binding 2 (LDB2) with EGR in the pathogenesis of schizophrenia. Embo Molecular Medicine. e12574 |
| Balan S, Ohnishi T, Watanabe A, et al. (2021) Role of an Atypical Cadherin Gene, Cdh23 in Prepulse Inhibition, and Implication of CDH23 in Schizophrenia. Schizophrenia Bulletin |
| Wada Y, Maekawa M, Ohnishi T, et al. (2020) Peroxisome proliferator-activated receptor α as a novel therapeutic target for schizophrenia. Ebiomedicine. 103130 |
| Maekawa M, Ohnishi T, Toyoshima M, et al. (2020) A potential role of fatty acid binding protein 4 in the pathophysiology of autism spectrum disorder. Brain Communications. 2: fcaa145 |
| Shimamoto-Mitsuyama C, Nakaya A, Esaki K, et al. (2020) Lipid Pathology of the Corpus Callosum in Schizophrenia and the Potential Role of Abnormal Gene Regulatory Networks with Reduced Microglial Marker Expression. Cerebral Cortex (New York, N.Y. : 1991) |
| Usui N, Iwata K, Miyachi T, et al. (2020) VLDL-specific increases of fatty acids in autism spectrum disorder correlate with social interaction. Ebiomedicine. 58: 102917 |
| Ide M, Ohnishi T, Toyoshima M, et al. (2019) Excess hydrogen sulfide and polysulfides production underlies a schizophrenia pathophysiology. Embo Molecular Medicine. e10695 |
| Ohnishi T, Balan S, Toyoshima M, et al. (2019) Investigation of betaine as a novel psychotherapeutic for schizophrenia. Ebiomedicine |